BioMedNewsBreaks Archive - Page 111 of 223

MondayNov 28, 2022 3:34 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss initiation of coverage of Aditxt with a buy rating and 12-month price target of $4 per share. “Personalized COVID-19 analytics can inform vaccinations, treatments and more. AditxtScore determines the coronavirus infection status of an individual, which can help patients and physicians make a variety of…

WednesdayNov 23, 2022 3:21 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP) is an oncology drug development company specializing in developing anti-cancer drugs for the treatment of primary and metastatic brain and central nervous system cancer. “The first half of fiscal 2022 saw the company make a number of clinical and operational advancements in its pursuit of treatment for glioblastoma multiforme (‘GBM’), according to CNS Pharmaceuticals CEO John Climaco. The company’s focus and priorities, Climaco emphasized, are firmly anchored in the advancement of its clinical development for its drug candidate Berubicin with the aim of bringing meaningful treatment to GBM patients. And as he separately told attendees at…

WednesdayNov 23, 2022 11:00 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During the past few months, the company has completed strategic steps to develop the drug, including appointing two new members of the management team with expertise in progressing drugs through the clinical phase and to the market; completing an FDA-required IND in order to move forward…

TuesdayNov 22, 2022 10:46 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has closed on a private placement with two healthcare-focused institutional investors. The placement included the sale of 1,818,185 INM common shares, which were issued at a purchase price of $3.30 per share (or prefunded warrant in lieu thereof); the shares were priced at-the-market under NASDAQ rules. The announcement also noted that InMed issued unregistered preferred investment options to the investors in the offering to purchase up to 3,272,733 common shares. The offering resulted in approximately $6 million in gross proceeds for…

MondayNov 21, 2022 12:25 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue, with initial data expected during the first quarter of 2023. “SPU-21 was shown to inhibit arthritic progression in a preclinical animal model, so we are proceeding to advance our research into human synovial tissue, where…

MondayNov 21, 2022 11:15 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the upcoming Biotech Showcase conference. The event is slated to take place Jan. 9-11, 2023, in San Francisco in parallel to the J.P. Morgan (“JPM”) 41st Annual Health Care Conference. Reichman will be available to meet potential partners, collaborators and investors. Interested parties should visit https://ibn.fm/p6eOA or https://ibn.fm/tcHsS or contact BiondVax Investor Relations at +972-8-930-2529 or ir@biondvax.com to request a one-on-one appointment. To view the full…

FridayNov 18, 2022 10:40 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has entered into a securities purchase agreement with two healthcare-focused institutional investors. The agreement outlines plans for the issuance and sale of 1,818,185 of INM common shares; the shares will be issued at a purchase price of $3.30 per share or prefunded warrant. In addition, the agreement notes that INM will issue unregistered preferred investment options to the same investors; those options include purchasing up to 3,272,733 additional common shares. According to the announcement, the company anticipates the private placement, which…

ThursdayNov 17, 2022 11:26 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has named Sarah Li as vice president of accounting and InMed controller; the change will be effective Nov. 20, 2022. Li is replacing Brenda Edwards, who has been serving as interim chief financial officer for the company. Edwards joined InMed in the interim contract role in March after the company’s CFO retired. “We are pleased to announce this promotion of Ms. Li to her new position as VP of Accounting and Controller,” said InMed president and CEO Eric A. Adams in…

ThursdayNov 17, 2022 10:50 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured in The Times of Israel Article

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. The company’s CEO Amir Reichman, as an international subject matter expert on pharmaceutical manufacturing and supply chains, has been consulted by members of U.S. Congress about related topics of interest. In 2021, Reichman participated in meetings in Washington, D.C., and earlier this year BiondVax welcomed a congressional delegation to its offices and GMP biologics manufacturing facility in Jerusalem. A Times of Israel article explains details about Congress’s interest in near-shoring the U.S. medical supply…

WednesdayNov 16, 2022 3:02 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent

HeartBeam (NASDAQ: BEAT), a cardiac technology company, has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for timely heart attack detection. The company today announced that the United States Patent and Trademark Office has allowed its patent for a 12-lead electrocardiogram (“ECG”) smartwatch-based monitor intended for detection of heart attacks and complex cardiac arrhythmias. The innovation expands HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting. “The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Close on $6M Private Placement Funding

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at the January 2023 Biotech Showcase

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Anticipated $6M Private Placement Funding

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Accounting VP, Controller

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured in The Times of Israel Article

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search